Cancer Chemotherapy and Pharmacology

, Volume 63, Issue 6, pp 1141–1145 | Cite as

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

  • Seong Yoon Yi
  • Young Suk Park
  • Hyo Song Kim
  • Hyun Jung Jun
  • Kyoung Ha Kim
  • Myung Hee Chang
  • Min Jae Park
  • Ji Eun Uhm
  • Jeeyun Lee
  • Se Hoon Park
  • Joon Oh Park
  • Jong Kyun Lee
  • Kyu Taek Lee
  • Ho Yeong Lim
  • Won Ki Kang
Original Article

Abstract

Purpose

The phase II study was conducted to evaluate the efficacy and safety of irinotecan as salvage single-agent chemotherapy in patients with advanced pancreatic cancer.

Methods

Patients with measurable metastatic pancreatic cancer, progressive after previous gemcitabine-based chemotherapy were treated with irinotecan 150 mg/m2 every 2 weeks. Treatment was repeated until disease progression or unacceptable toxicity.

Results

Between March 2004 to February 2007, 33 patients were registered and treated with irinotecan monotherapy. The patients’ median age was 59 years (range 36–70) and two had an ECOG performance status of 2. A total of 167 chemotherapy cycles were delivered (median, 4; range 2–12). In an intent-to-treat analysis, three (9%) confirmed partial response and 13 patients with stable disease were observed for a disease control rate of 48%. The median progression-free and overall survivals were 2.0 months (95% CI, 0.7–3.3) and 6.6 months (95% CI, 5.8–7.4), respectively. Toxic effects were mainly gastrointestinal (nausea in 64% of patients, diarrhea in 36%), Toxicity profiles were generally predictable and manageable, and there was no treatment-related death.

Conclusions

Second-line chemotherapy with single-agent irinotecan is marginally effective and well tolerated regimen for gemcitabine-pretreated patients with advanced pancreatic cancer.

Keywords

Pancreatic cancer Irinotecan Second line chemotherapy Gemcitabine failure 

References

  1. 1.
    Bae JM, Won YJ, Jung KW, Park JG (2002) Annual report of the Korean central cancer registry program 2000. Cancer Res Treat 34:77–83Google Scholar
  2. 2.
    Bissery MC, Vrignaud P, Lavelle F, Chabot GG (1996) Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7:437–460PubMedCrossRefGoogle Scholar
  3. 3.
    Boeck S, Heinemann V (2008) Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol 26:1178–1179 author reply 1179PubMedCrossRefGoogle Scholar
  4. 4.
    Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  5. 5.
    Creemers GJ, Lund B, Verweij J (1994) Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 20:73–96PubMedCrossRefGoogle Scholar
  6. 6.
    Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047PubMedCrossRefGoogle Scholar
  7. 7.
    Ducreux M, Boige V, Malka D (2007) Treatment of advanced pancreatic cancer. Semin Oncol 34:S25–S30PubMedCrossRefGoogle Scholar
  8. 8.
    Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143–151PubMedCrossRefGoogle Scholar
  9. 9.
    Kang SP, Saif MW (2008) Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP 9:83–90PubMedGoogle Scholar
  10. 10.
    Kelly DM, Benjamin IS (1995) Pancreatic carcinoma. Ann Oncol 6:19–28PubMedGoogle Scholar
  11. 11.
    Klapdor R, Fenner C (2000) Irinotecan(Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer. Anticancer Res 20:5209–5212PubMedGoogle Scholar
  12. 12.
    Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783PubMedCrossRefGoogle Scholar
  13. 13.
    Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914PubMedCrossRefGoogle Scholar
  14. 14.
    Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V (2006) A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587–592PubMedCrossRefGoogle Scholar
  15. 15.
    Taieb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, Fallik D, Spano JP, Landi B, Lledo G, Desrame J (2007) FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 18:498–503PubMedCrossRefGoogle Scholar
  16. 16.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  17. 17.
    Ueno H, Okusaka T, Funakoshi A, Ishii H, Yamao K, Ishikawa O, Ohkawa S, Saitoh S (2007) A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 59:447–454PubMedCrossRefGoogle Scholar
  18. 18.
    Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W (2003) Irinotecan plus raltitrexed vs. raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88:1180–1184PubMedCrossRefGoogle Scholar
  19. 19.
    Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boue A, Verweij J (1995) Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 6:129–132PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Seong Yoon Yi
    • 1
  • Young Suk Park
    • 1
  • Hyo Song Kim
    • 1
  • Hyun Jung Jun
    • 1
  • Kyoung Ha Kim
    • 1
  • Myung Hee Chang
    • 1
  • Min Jae Park
    • 1
  • Ji Eun Uhm
    • 1
  • Jeeyun Lee
    • 1
  • Se Hoon Park
    • 1
  • Joon Oh Park
    • 1
  • Jong Kyun Lee
    • 2
  • Kyu Taek Lee
    • 2
  • Ho Yeong Lim
    • 1
  • Won Ki Kang
    • 1
  1. 1.Division of Hematology-Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea
  2. 2.Division of Gastroenterology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea

Personalised recommendations